310 Shares in Eli Lilly and Company $LLY Purchased by Sonata Capital Group Inc.

Key Points

• Sonata Capital Group Inc. acquired 310 shares of Eli Lilly and Company, valued at approximately $242,000, during the second quarter.
• Eli Lilly's recent earnings report showed $6.31 EPS and revenue of $15.56 billion, significantly surpassing analysts' expectations.
• Analysts have issued mixed ratings on Eli Lilly, with the average consensus rating being a "Moderate Buy" and a target price of $938.61.

Sonata Capital Group Inc. bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 310 shares of the company's stock, valued at approximately $242,000.

Other institutional investors have also modified their holdings of the company. LifeWealth Investments LLC lifted its holdings in shares of Eli Lilly and Company by 14.1% in the 2nd quarter. LifeWealth Investments LLC now owns 803 shares of the company's stock worth $626,000 after buying an additional 99 shares during the period. OLD Point Trust & Financial Services N A increased its holdings in shares of Eli Lilly and Company by 21.3% in the 2nd quarter. OLD Point Trust & Financial Services N A now owns 228 shares of the company's stock valued at $178,000 after acquiring an additional 40 shares during the period. Granite Harbor Advisors Inc. grew its position in shares of Eli Lilly and Company by 2.9% in the 2nd quarter. Granite Harbor Advisors Inc. now owns 2,145 shares of the company's stock worth $1,672,000 after buying an additional 61 shares during the last quarter. Forum Financial Management LP grew its holdings in Eli Lilly and Company by 5.2% in the second quarter. Forum Financial Management LP now owns 8,805 shares of the company's stock worth $6,864,000 after purchasing an additional 437 shares during the last quarter. Finally, Meadow Creek Wealth Advisors LLC increased its position in Eli Lilly and Company by 129.8% during the 2nd quarter. Meadow Creek Wealth Advisors LLC now owns 3,960 shares of the company's stock valued at $3,087,000 after buying an additional 2,237 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on LLY shares. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. JPMorgan Chase & Co. lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. Finally, The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $938.61.

Eli Lilly and Company Trading Up 1.6%

Shares of LLY stock opened at $812.33 on Thursday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company's 50-day moving average price is $762.81 and its 200-day moving average price is $766.75. The stock has a market cap of $768.84 billion, a price-to-earnings ratio of 53.09, a PEG ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 in the last 90 days. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.